Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

SIM-1803-1A

Generic Name: SIM-1803-1A

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Phase 1

Posted: 2020/12/17

Sponsor:Jiangsu Simcere Phar...

ID:NCT04671849

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Next-Generation TRK Inhibitors Show Promise in Treating NTRK Fusion-Positive Cancers

7 months ago

NTRK gene fusions, though rare, represent a significant therapeutic target across multiple cancer types, with first-generation TRK inhibitors showing remarkable response rates and durability in clinical trials.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy